查看文章

COVID-19, a pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected over 25 million confirmed patients with almost 1 million fatalities (3.4%)(https://coronavirus. jhu. edu/map. html). Numerous reports have discussed the role of cytokine storm in the disease pathogenesis and prognosis, with Interleukin-6 (IL-6) as the apparent primary contributor to this storm. 1–3 Subsequently, Tocilizumab (Actemra®), as a humanized monoclonal antibody, showed promising results in decreasing the inflammatory responses and improving patient’s conditions in many retrospective clinical trials, which were limited to small sample sizes. 4–7 The primary laboratory indicator that determines the proper time to start Tocilizumab treatment should be the blood IL-6 level, which unfortunately is unavailable in all countries or treatment centers. Accordingly, many hospitals have adopted different …